National Substance Register for Medicinal Products (NSL) Information Structure Jeff Martin, Enterprise architect 018-17 46 00.

Slides:



Advertisements
Similar presentations
Revision of WIPO Standard ST.14 Committee on WIPO Standards, third session Geneva 15 – 19 April 2013 Anna Graschenkova Standards Section.
Advertisements

1 XML Standardization: Progress Report on WIPO Standards USPTO May 12, 2014 CWS – Fourth Session.
0 Chicago, IL March 6 th, 2007 Use Case Requirements, Design and Standards Selection HITSP Use Case Requirements, Design and Standards Selection Date:
Development of Guidance Documents Jennifer Scharpf, M. P. H
Additives and Contaminants (incl. Flavourings, Extraction Solvents, Enzymes and Ionising Radiation) 30 March 2011.
Meldingen 30 november 2011 Anja van Haren EudraVigilance Coördinator Informatiebijeenkomst nieuwe wetgeving farmacovigilantie.
Christine Simmon Senior Vice President, Policy & Strategic Alliances Generic Pharmaceutical Association November 6, 2014 Biologics Naming.
1 The Practice of Granting SUPPLEMENTARY PROTECTION CERTIFICATES in the German Patent and Trademark Office (GPTO) Andrea Münzberg Chemical Patent Division.
New ISO projects Joint meeting HL7, IHE and ISO Pharmacy groups Leonora Grandia, Z-Index.
Mosby items and derived items © 2007 by Mosby, Inc., an affiliate of Elsevier Inc. Chapter 4 Prescription Writing.
The New EMC Directive 2004/108/EC and the DTI transposition Brian Jones and Peter Howick.
Procedures to Develop and Register Data Elements in Support of Data Standardization September 2000.
Utility Requirement in Japan Makoto Ono, Ph.D. Anderson, Mori & Tomotsune Website:
ISO as the metadata standard for Statistics South Africa
DRAFT Guidance for Industry: Providing Regulatory Submissions in Electronic Format – Drug Establishment Registration and Drug Listing Denise Sánchez, J.D.,
Institute of Biotechnology and Antibiotics (IBA) Presented by Małgorzata Kęsik Assistant Professor at IBA.
Subsequent Entry Biologics (SEBs) – Canada Presentation to AIPLA Biotechnology Committee January 25, 2012 Daphne C. Lainson
Pre-registration, data-sharing and SIEFs Geert Dancet REACH Workshop – Brussels 18/09/2008.
REACH Industry Update WERCS US User Group Meeting 2008 Dr. Erwin Annys Sr. Advisor Product & Innovation Policy.
H. Lundbeck A/S21-Sep-151 Pharmacovigilance during clinical development SAE reporting, ASUR and PSUR IFF Seminar, 21. February 2007.
ICH V1 An FDA Update Min Chen, M.S., RPh Office of Drug Safety Center for Drug Evaluation and Research FDA January 21, 2003.
Support for the Modernisation of the Mongolian Standardisation system – EuropeAid/134305/C/SER/MN Training on standardisation Support to the Modernisation.
New Implementing Regulation DG Enterprise on the Administrative Requirements for the approval and market surveillance of 2- or 3-wheel vehicles and quadricycles.
ISO Environmental management — Life cycle assessment — Data documentation format.
DMF Procedures and Communication between API, FP Manufacturers and Regulatory Authorities Jean-Louis ROBERT National Health Laboratory L – 1011 LUXEMBOURG.
Communication in the Supply Chain
An agency of the European Union Presented by: Emer Cooke and Truus Janse-de Hoog Update on Transparency Progress report from HMA/EMA TF on Transparency.
CLP Up-date (The classification, labelling and packaging of chemical substances and mixtures) (DIRECTIVE 2008/112/EC OF THE EUROPEAN PARLIAMENT AND OF.
Proposed Gluten Regulations in Argentina Excipient Realities and Global Requirements.
Malaysia Update on “draft” proposal for the Environmentally Hazardous Substance (“EHS”) Notification and Registration Scheme.
Federal agency for medicines and health products EC REGULATION 1901/2006 ON MEDICINAL PRODUCTS FOR PAEDIATRIC USE AND HOMEOPATHIC MEDICINAL PRODUCTS Marie-Anne.
© AL IPA/EDQM/IDMA Symposium 2007, All rights reserved The Ph. Eur. policy on impurities Dr Andrea Lodi Deputy Head, Laboratory Department, EDQM, Council.
Ivowen Ltd1 Ivowen Limited Preparation and Submission of a Traditional Herbal Medicinal Product Application.
SDC JE What is a Data Registry? v A place to keep facts about characteristics of data that are necessary to clearly describe, inventory,
1 October, 2015 HL 7 Working Group Meeting. FDA UDI Rule – 9/24/2013 Unique device identifier (UDI) means an identifier that adequately identifies a device.
Transatlantic Administrative Simplification Workshop European Preparatory Roundtable Suzette Kox EGA Senior Director Scientific Affairs.
ECB INFODAYS, Zagreb, Croatia, December 2006 EU Notification Scheme (New Substances) and New Chemicals Database ECB INFODAYS, Zagreb, December.
PAHO has created a mechanism in order that the countries that do not have aptitude to guarantee generic insurances accede to them in an immediate.
DMF Procedures and Communication between API, FFP Manufacturers and Regulatory Authorities Jean-Louis ROBERT National Health Laboratory L – 1011 LUXEMBOURG.
Compassionate use programs and the European regulatory system Filip Josephson M.D., Ph.D. Clinical Assessor.
Czech National Information Centre (Help-Desk) REACH Jan Kolář April 2009.
IDMP Overview December 2015.
REACH & CLP Downstream user overview 1. Purpose of this presentation 2 This presentation, with notes, was prepared by.
PHC Meeting the global challenge of unique identification of medicinal products SMS, RMS and OMS : Common Terminologies for enabling ISO IDMP.
POST APPROVAL CHANGE MANAGEMENT PROTOCOLS IN THE EUROPEAN UNION
New legislation impacting IMP
Representation of Hypersensitivity, Allergy and adverse reactions in SNOMED CT Bruce Goldberg, MD, PhD.
Information on Medicinal Products
Biologic Medicines.
REACH 2018 Find your co-registrants and prepare to register jointly.
OICA input on software updates to UN TF CS/OTA
DIA Clinical Safety and Pharmacovigilance Community
Draft Recommendations & Roadmap
Session 6. overview of annotated outline of new guidelines
Inaugural Expert Council Meeting at E.M.A. London June 25, 2015
Median 25th and 75th percentile
Gibraltar Financial Services Commission
EU SUBMISSION BY Haripriya & Revathy.
Percentage Key Message
Updates to Expedited Review Procedures
EMA: The European Medicines Agency
Activity on environmental objectives and exemptions
Recommendations to facilitate assessment of new application procedures
TOP 5d) Floods Directive reporting - INSPIRE progress -
EU Food Safety Requirements: - Hygiene of Foodstuffs -
VICH Guidelines on stability: OVERVIEW
VICH Guidelines on stability: OVERVIEW
Presentation transcript:

National Substance Register for Medicinal Products (NSL) Information Structure Jeff Martin, Enterprise architect

Background: Companies in the EU must report human medicinal product information to the EMA New regulations for pharmacovigilance are meant to increase transparency and improve cooperation in the EU regarding management of adverse reactions Medicinal product information to be reported: –Information on medicinal products –Information on ingredients –Information on adverse reactions Product information shall be reported in a defined format by 1 July 2012 (Article 57:2 in 726/2004)

EMA: Format specification Shall be formatted in accordance with a group of ISO-standards –Together they are called IDMP – Identification of Medicinal Products Product information will be stored in EudraVigilance in the Extended EudraVigilance Medicinal Product Dictionary (xevmpd) –Format published 1 July 2011 by the EMA –Medicinal products – emaxevmpd.xsd –Substances – emaxevmpd_ssi.xsd

Standards in the IDMP package: Health informatics -- Identification of medicinal products -- Data elements and structures for the unique identification and exchange of regulated information on substances Health informatics -- Identification of medicinal products -- Data elements and structures for the unique identification and exchange of regulated information on pharmaceutical dose forms, units of presentation, routes of administration and packaging Health informatics -- Identification of medicinal products -- Data elements and structures for the unique identification and exchange of units of measurement Health informatics -- Identification of medicinal products -- Data elements and structures for the unique identification and exchange of regulated medicinal product information Health informatics -- Identification of medicinal products -- Data elements and structures for the unique identification and exchange of regulated pharmaceutical product information All are in phase (reached this status ) – “International Standard under publication” which is the last phase before final publication. Minor editorial changes may still occur.

BUT MPA has decided to use this structure now Substance Information in PharmaPackage The requested substance information was VERY comprehensive After discussions with industry, the EMA decided (Feb 2012) that the requirement for highly detailed substance information should be delayed Substance information will be required from industry in the detailed format eventually (2015?)

Information Structure – Basic Principles Based on ISO 11238: Health informatics -- Identification of medicinal products -- Data elements and structures for the unique identification and exchange of regulated information on substances Standard interpreted by the EMA – published an XSD file in July 2011 –emaxevmpd_ssi.xsd –ssi = Structured Substance Information

MPAs interpretation of the ISO standard ISO standard is much more comprehensive than what NSL needs Cut down but the basic structure was kept –SEnsl-ssi.xsd – scheme for ISO part No place for specific Swedish information needed in NSL e.g. recommended Swedish name and substance relationship (parent-child relationship) –Separate scheme (.xsd) to avoid breaking compatibility with the EMA –SEnsl-other.xsd Several other files for management of pre-defined values (dictionaries) were added

NSL package – consists of a ZIP file with 16 files SEnsl-ssi.xsd and SEnsl-ssi.xml –Substance data in ISO structures SEnsl-other.xsd and SEnsl-other.xml –Substance data for other information SEnsl-lexicon.xsd –Scheme for management of dictionaries 11 schemes with dictionaries –Including Swedish translations of ATC codes: atc-code-lx.xsd

Basic structure: SEnsl-ssi.xsd Guidance Notes and Business Rules: Chapter 4: Structured substance information Detailed guidance on the electronic submission of information on medicinal products for human use by marketing authorisation holders to the European Medicines Agency in accordance with Article 57(2), second subparagraph of Regulation (EC) No. 726/2004 Version 2.0 (1 sep 2011) Document removed from EMAs website 5 March 2012 but is available on nsl.mpa.se. Read the examples – they are easier to understand than the guidance notes. nsl.mpa.se

Basic structure for ISO compatible information in SEnsl-ssi.xsd Substance – one instance for each published substance Envelope – contains all the substances timestamp – when the file was generated

Basic structure for ISO-compatible information in SEnsl-ssi.xsd cv = controlled vocabulary (ISO) = dictionary Not obligatory

SEnsl-ssi.xsd Substance-id – unique id from EudraVigilance –NOT the substance-id from NPL/NSL –Not obligatory –Duplicated under substance-codes SE national ID (SeNSLid) for the substance is under substance-codes –same ID as in NPL

SEnsl-ssi.xsd Classification of substances according to the ISO standard – subst-class-iso-lx.xsd –Single –Mixture –Specified substance Definitions are in: Chapter 6: Definitions I Detailed guidance on the electronic submission of information on medicinal products for human use by marketing authorisation holders to the European Medicines Agency in accordance with Article 57(2), second subparagraph of Regulation (EC) No. 726/2004 (Ref 2)

Substance-classification-cv (ISO) – Single substance "Refers to a substance that can be described by a single representation or set of descriptive elements. A single substance can be described using one or more of five types of elements; chemical, protein, nucleic acid, polymer and structurally diverse substances." (Ref 2).

Substance-classification-cv – Mixture substance a type of polydisperse substance that is a combination of single substances isolated together or produced in the same synthetic process. Single substances of diverse origin that are brought together and do not undergo a chemical transformation can be defined as multi- substance materials (Group 1 specified substances) and not as mixture substances. Gentamicin can be defined as a mixture substance of Gentamicin C1A, Gentamicin C1, and Gentamicin C2. Simethicone which consists of dimethicone and silicon dioxide should not be defined as a mixture substance since these are diverse materials brought together to form a product – Specified substance (Ref 2)

Substance-classification-cv – Specified substance Refers to groups of elements which describe multi- substance materials and specify further information on substances and multi-substance materials relevant to the description of medicinal products –There are three groups (group 1, 2 & 3) (Ref 2)

Specified substance – group 1 Material that contains multiple substances, solvents used in the preparation of herbal or allergenic extracts, specific marker or signature substances present in materials derived from biological matrices This grouping of constituents allows for the definitions of many materials in commerce that are used in the formulation of medicinal products –Paracetamol with 3 % povidone –Insulin human isophane (Ref 2)

Specified substance – group 2 Refers to the manufacturer of either a substance or a specified substance group 1, along with minimal manufacturing information Group 2 elements would allow the tracking of the substance to the manufacturer, e.g. biosimilar products, synthetic vs recombinant peptides May be used in NSL – e.g. for biotechnological and herbal substances (Ref 2)

Specified substance – group 3 Refers to the grade of the material along with the source that defines the given grade Group 3 elements shall be used to distinguish specific pharmacopoeial and technical grades of material, e.g. Sterile Water for Injection USP Will not be used in NSL – too detailed (Ref 2)

SEnsl-ssi.xsd – name of the substance including synonyms name 1-many relation – there must be at least one but may occur as many times as neccesary.

Substance-name-type-cv (ISO) –Code –Official Name –Other Name –Translation Language-cv (ISO) –SWE –ENG –ZXX for no language – used when the name is a code or a proprietary name

SEnsl-ssi.xsd – official name: when the name comes from an official source e.g. Ph.Eur.

Official name If the name is official, then more details are provided –Official-name-type-cv (ISO): e.g. INN –Official-name-status-cv (ISO): e.g. Current, superceded

SEnsl-ssi.xsd – different codings for the substance code There must always be at least one since our SeNSLid is stored there.

Code-system-cv (ISO) in NSL ATC CAS FDA’s Unique Ingredient Identifier (UNII) from their Substance Registration System (SRS) Snomed-CT EVMPD – code from EudraVigilance – same as substance-id Swedish National Drug Substance Registry ID –The code used in NPL - SeNSLid

SEnsl-ssi.xsd – version: latest update date NOTE – latest update is not implemented yet – will come in the beginning of November

SEnsl-ssi.xsd – Reference information: allows a comment and further classification

SEnsl-ssi.xsd – more ISO classification Will not be used for now

Substance-classification-cv (ISO) Same as previously –Single substance –Mixture substance –Specified substance

Substance-classification-type-cv (ISO) When substance-classification is Single or Mixture, substance- classification-type comes from Substance Type CV –Chemical –Nucleic Acid –Protein –Polymer –Structurally Diverse –Mixture When substance-classification is Specified substance, substance- classification-type comes from Specified Substance Type CV –Specified Substance Level 1 –Specified Substance Level 2 –Specified Substance Level 3 - See ch 4, p 26 in Ref 2 for more details

Structurally Diverse Substance A type of polydisperse substance isolated from a single source that is a complex mixture which cannot be described as a mixture of a limited number of single substances Protein mixtures containing a large number of diverse sequences such as polyclonal immunoglobulins shall be defined as structurally diverse substances Examples: - Vaccine - Immunoglobin - Blood derived - Herbal - Allergen - Cell therapy - Other

substance-classification = Mixture When the substances in a Mixture are of the same type, then substance-classification- type should be the same as the substances –E.g. two Chemicals type= Chemical If the substances are of different types – E.g. chemical and protein type = Mixture

Substance-classification-subtype-cv (ISO) Allergen Blood Derived Cell Therapy Gene Therapy Herbal Monoclonal Antibody Multiple Substances Not Applicable Other Polyclonal Immunoglobulin Tissue Engineered Vaccines

Additional file - SEnsl-other.xsd Contains information not in the ISO standard –Recommended Swedish name –Alternative recommended Swedish name –National Swedish narcotic classification –Substance relationship(s) (parent–child)

SEnsl-other.xsd Substance – one instance for each published substance Envelope – contains all the substances timestamp – when the file was generated

Coupling between the files SeNSLid – shall be coupled to this substance-code NOT substance-id X SEnsl-other.xsd SEnsl-ssi.xsd

Coupling between the files, cont’d Remember: the substance-id is the ID that comes from EMA/EudraVigilance and not the ID that we have used in NPL. That ID is saved as a substance- code SeNSLid that is used here is the SAME ID that has always been used in NPL

SEnsl-other.xsd – Recommended name One recommended name in Swedish Zero to many alternative* recommended Swedish names *Alternative recommended name to be used in e.g. text.

SEnsl-other.xsd – narcotic classification NarcoticClass – same values as in NPL Values: Not classified as a narcotic I II III IV V

Definitions: narcotic classifications Not classified as a narcotic I - Narcotics that do not occur in medicinal products. II - Narcotic. Substances with greater abuse potential and limited therapeutic use. III - Narcotic. Preparations exempted from certain provisions are listed in the Annex to LVFS 2011:9 IV - Narcotic. Substances with lower abuse potential and broad therapeutic use. V - Narcotic under Swedish law only.

SEnsl-other.xsd – parent–child A parent can have several children A child can have several parents Dictionary values: Has child Has parent

SEnsl-other.xsd – parent-child Salts of substances will be children. Hydrates/solvates will be children. Hydrated/solvated salts of substances are also children (not grandchildren). Salts of two active substances will received two parents. –Very rare –physostigmine salicylate: has both physostigmine and salicylic acid as parents Inorganic salts will not be given children, e.g. calcium will not be given calcium carbonate as a child substance.

Example - Clopidogrel Two files –SEnsl-ssi.xml based on SEnsl-ssi.xsd –SEnsl-other.xml based on SEnsl-other.xsd

Clopidogrel in SEnsl-ssi.xml Substance Class CV SUB13395MIG code text name of CV NOTE – substance-id (from EudraVigilance) and ISO substance classification are not yet in NSL

Clopidogrel in SEnsl-ssi.xml – substance-name clopidogrel <substance-name-type-cv term-id=" " term-revision-num="1" term-lang="en" term-english-equiv="Official Name"> Substance Name Type CV eng <official-name-type-cv term-id=" " term-revision-num="1" term-lang="en" term-english-equiv="International Non-proprietary Name">Source CV <official-name-status-cv term-id=" " term-revision-num="1" term-lang="en" term-english-equiv="Current">Source CV

Clopidogrel in SEnsl-ssi.xml – substance-code Code System CV Status CV

Clopidogrel in SEnsl-ssi.xml – substance-code - SeNSLId IDE4POFLUB372VERT1 <code-system-cv term-id="SENSLIDSENSL" term-revision-num="1" term-lang="en" term-english-equiv="Swedish National Drug Substance Registry ID"> Code System CV Status CV NOTE – neither SeNSLid or Snomed-CT are in the list of codes in the ISO code list from EMA – the MPA has defined the codes

Clopidogrel in SEnsl-ssi.xml - version Date when the substance information was last changed. Applies for all the substance information

Clopidogrel in SEnsl-ssi.xml – substance- classification Substance Class CV Substance Type CV Substance subtype CV NOTE – ISO classification is not in NSL yet

Clopidogrel in SEnsl-other.xml - SeNSLid IDE4POFLUB372VERT1

Clopidogrel in SEnsl-other.xml – RecommendedName klopidogrel rec RecommendedNameClassLx: rec = Recommended Swedish name altrec = Alternative recommended Swedish name There will always be a recommended Swedish name. Eventual alternative recommended Swedish names will be added during the rest of 2012.

Clopidogrel in SEnsl-other.xml – NarcoticClass 0

Clopidogrel in SEnsl-other.xml – SubstanceSubstanceRelation IDSXARUW1AYQ2YQMSR CHILD SeNSLid that clopidogrel is related to, in this case clopidogrel hydrochloride Clopidogrel has child clopidogrel hydrochloride

SubstanceSubstanceRelation in SEnsl-other.xml Clopidogrel IDE4POFLUB372VERT1 0 IDSXARUW1AYQ2YQMSR CHILD Clopidogrel hydrochloride IDSXARUW1AYQ2YQMSR 0 IDE4POFLUB372VERT1 PARENT

References Ref 1. Chapter 4: Structured substance information, Detailed guidance on the electronic submission of information on medicinal products for human use by marketing authorisation holders to the European Medicines Agency in accordance with Article 57(2), second subparagraph of Regulation (EC) No. 726/2004 Version 2.0 (1 sep 2011) Ref 2. Chapter 6: Definitions I Detailed guidance on the electronic submission of information on medicinal products for human use by marketing authorisation holders to the European Medicines Agency in accordance with Article 57(2), second subparagraph of Regulation (EC) No. 726/2004,